Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests

First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumeration Expands CNSide contracted payer access to approximately 164 million covered lives HOUSTON, Oct. 08,